Tags

Type your tag names separated by a space and hit enter

Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia.
Nord J Psychiatry. 2020 Jun 04 [Online ahead of print]NJ

Abstract

Introduction: Cognitive impairment is a core feature of schizophrenia. The effects of atypical antipsychotics on the cognitive functions of patients with first-episode schizophrenia have not been comprehensively investigated so far. This study aims to compare neurocognitive effects of risperidone, olanzapine, and aripiprazole for first-episode schizophrenia.

Methods:

The study was a multicenter, randomized, open-label clinical trial. 546 patients were randomly divided into three medication groups, and followed up for 1 year. Cognitive performance was evaluated with a neuropsychological test battery. The Clinical trials.gov ID of the study is NCT01057849.

Results:

At 6 months, treatment resulted in significant improvements in all three groups in most cognitive domains except verbal learning and memory. At 12 months, three treatment groups had further improvements in three cognitive domains, but visual learning and memory performance dropped back to baseline.

Conclusion:

All three atypical antipsychotics tested in the study can potentially improve cognitive performance in first-episode schizophrenia, but no significant difference in the degree of improvement was found between drugs.

Authors+Show Affiliations

Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China. Qingdao Mental Health Center, Qingdao University, Shandong, 266034, China.Peking University, Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.Peking University Sixth Hospital, Beijing, 100191, China. Peking University Institute of Mental Health, Beijing, 100191, China. NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 100191, China. The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, 100191, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32496921

Citation

Hou, Yanyan, et al. "Neurocognitive Effects of Atypical Antipsychotics in Patients With First-episode Schizophrenia." Nordic Journal of Psychiatry, 2020, pp. 1-8.
Hou Y, Xie J, Yuan Y, et al. Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. Nord J Psychiatry. 2020.
Hou, Y., Xie, J., Yuan, Y., Cheng, Z., Han, X., Yang, L., Yu, X., & Shi, C. (2020). Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. Nordic Journal of Psychiatry, 1-8. https://doi.org/10.1080/08039488.2020.1771767
Hou Y, et al. Neurocognitive Effects of Atypical Antipsychotics in Patients With First-episode Schizophrenia. Nord J Psychiatry. 2020 Jun 4;1-8. PubMed PMID: 32496921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. AU - Hou,Yanyan, AU - Xie,Jiaheng, AU - Yuan,Yanbo, AU - Cheng,Zhang, AU - Han,Xue, AU - Yang,Lei, AU - Yu,Xin, AU - Shi,Chuan, Y1 - 2020/06/04/ PY - 2020/6/5/entrez PY - 2020/6/5/pubmed PY - 2020/6/5/medline KW - Neurocognitive function KW - atypical antipsychotics KW - first-episode schizophrenia SP - 1 EP - 8 JF - Nordic journal of psychiatry JO - Nord J Psychiatry N2 - Introduction: Cognitive impairment is a core feature of schizophrenia. The effects of atypical antipsychotics on the cognitive functions of patients with first-episode schizophrenia have not been comprehensively investigated so far. This study aims to compare neurocognitive effects of risperidone, olanzapine, and aripiprazole for first-episode schizophrenia.Methods: The study was a multicenter, randomized, open-label clinical trial. 546 patients were randomly divided into three medication groups, and followed up for 1 year. Cognitive performance was evaluated with a neuropsychological test battery. The Clinical trials.gov ID of the study is NCT01057849.Results: At 6 months, treatment resulted in significant improvements in all three groups in most cognitive domains except verbal learning and memory. At 12 months, three treatment groups had further improvements in three cognitive domains, but visual learning and memory performance dropped back to baseline.Conclusion: All three atypical antipsychotics tested in the study can potentially improve cognitive performance in first-episode schizophrenia, but no significant difference in the degree of improvement was found between drugs. SN - 1502-4725 UR - https://www.unboundmedicine.com/medline/citation/32496921/Neurocognitive_effects_of_atypical_antipsychotics_in_patients_with_first-episode_schizophrenia L2 - http://www.tandfonline.com/doi/full/10.1080/08039488.2020.1771767 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.